Odyssey Group International, Inc. is a unique, medical device technology holding company, publicly traded on the OTC under the ticker ODYY. We develop and acquire life saving medical products with a technological and clinical advantage.
- Loading stock data...
Odyssey Group plans to develop a neurosteroid (PRV-002) for concussion treatment in humans. PRV-002 is a fully synthetic non-naturally occurring neurosteroid administered through the nasal cavity. PRV-002 carries with it equivalent, if not superior, neuroprotective effects compared to related neurosteroids.
We Build and Acquire assets in medical technologies with a substantial market opportunity across the globe.
The Company’s product technologies are diverse, there are three different medical products in development. The Company has two devices being designed for large market segments, one for the cardiology market and one for a home use choking rescue devices. The Company has also partnered with Prevacus, Inc., who has been developing a nasal spray to treat concussions and other brain related medical issues such as Nieman Picks type C disease.
Get the latest information on Odyssey Group International, Inc. (OTC: ODYY) and its filings.
Odyssey Group International, Inc. is always acquiring distinct assets, intellectual property, and technologies.
Please fill in the form and we will get back to you.
Odyssey Group International, Inc.
2372 Morse Avenue
Irvine, CA 92614